Response to “CYP2C9 Polymorphism is Not a Major Determinant of Bosentan Exposure in Healthy Volunteers”
Markova, S M, Schwartz, J B, Kroetz, D LVolume:
95
Language:
english
Journal:
Clinical Pharmacology & Therapeutics
DOI:
10.1038/clpt.2013.239
Date:
March, 2014
File:
PDF, 138 KB
english, 2014